Revenio Group Corporation

REG1V · Nasdaq Helsinki · Healthcare

10.40EUR −1.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: −55.0%

Performance

1 month

−34.3%

1 year

−55.0%

3 years, per year

−19.1%

5 years, per year

−27.4%

Largest fall, 3 years

−71.6%

Below the peak now

−84.7%

Volatility, 1 year

44.1%

Return with dividends reinvested.

Key figures

P/E

23.3

P/B

2.1

Dividend yield

0.0%

Return on equity

+8.8%

Net margin

+10.7%

Market value

351 m USD

Quality, value and trend

Where Revenio Group stands against every Nordic stock today. 100 is best.

Quality71

Profitability and a sound balance sheet over time. Better than 71% of Nordic stocks.

Value45

The price measured against earnings, assets and cash flow. Better than 45% of Nordic stocks.

Trend9

The price development over the past year. Better than 9% of Nordic stocks.

Combined31

Quality, value and trend together. Better than 31% of Nordic stocks.

About Revenio Group

Revenio Group Corporation is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 760 employees.

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis